Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
Home > Inhibitors & Agonists > Epigenetics > Histone Demethylase

Vafidemstat (ORY-2001)

  Cat. No.:  DC11106   Featured
Chemical Structure
1357362-02-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Vafidemstat (ORY-2001) is an oral, brain penetrant drug that inhibits LSD1 and MAOB by reducing cognitive impairment, including memory loss and neuroinflammation. It also has neuroprotective effects.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 1357362-02-7
Chemical Name: 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-[(1R,2S)-2-[4-(phenylmethoxy)phenyl]cyclopropyl]-
Synonyms: ORY2001,ORY 2001,ORY-2001
SMILES: O1C(N)=NN=C1CN[C@H]1C[C@@H]1C1=CC=C(OCC2=CC=CC=C2)C=C1
Formula: C19H20N4O2
M.Wt: 336.395
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Vafidemstat is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.
Target: LSD1/MAO-B[1]
In Vitro: Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2].
References: [1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC11703 T-3775440 hydrochloride T-3775440 hydrochloride is a novel potent, selecitve, irreversible LSD1 inhibitor with IC50 of 2.1 nM.
DC11400 Seclidemstat（SP-2577） Seclidemstat(SP-2577) is a potent LSD1 inhibitor, with a mean IC50 of 127 nM.
DC7636 RN-1 Hydrochloride RN-1 is an inhibitor of lysine specific demethylase 1 (LSD1); exhibits selectivity for LSD1 over monoamine oxidase (MAO)-A and MAO-B (IC50 values are 70 nM, 0.51 and 2.79 μM respectively.
DC5204 OG-L002 OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.
DC7740 ML-324 ML-324 is a JMJD2 histone demethylase inhibitor (JMJD2 IC50 = 920 nM)
DC11106 Vafidemstat (ORY-2001) Vafidemstat (ORY-2001) is an oral, brain penetrant drug that inhibits LSD1 and MAOB by reducing cognitive impairment, including memory loss and neuroinflammation. It also has neuroprotective effects.
DC10586 KDM4D-IN-1 KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC50 value of 0.41±0.03 μM.
DC7614 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.
DC8491 GSK2879552 GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
DC8385 Disodium (R)-2-Hydroxyglutarate Disodium (R)-2-Hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases with Ki of 0.628 mM.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia